Jiangsu Maikai Biotechnology Co., Ltd. was established in November 2021 with a registered capital of 15 million yuan. It is an emerging research and development enterprise that relies on chemical organic synthesis and biosynthetic technology, and is committed to the research and innovation of a series of cutting-edge products such as rare diseases, orphan drugs, malignant tumors, pediatric drugs, and drugs that can prolong human life and improve quality of life. It also explores and develops small nucleic acid drugs, monoclonal antibodies, bispecific and tertiary antibody clones.